Dual Trigger for Elective Fertility Preservation
Launched by FUNDACIÓN SANTIAGO DEXEUS FONT · Jul 29, 2021
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
Elective oocyte cryopreservation (EOC) has been gaining increasing importance in the last few years, driven by the widespread information regarding the concept of 'age-related fertility decline', as well as the availability of efficient contraception and women's increasing educational and professional aspirations. Considering the similar clinical outcomes regarding live birth rate after vitrified-warmed and fresh oocytes and the proven cost-effectiveness of this approach, oocyte banking is now considered an efficient technique in assisted reproduction.
Previous studies have shown that both...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Able and willing to sign the Patient Consent Form and adhere to study visitation schedule
- • antral follicle count (AFC) \<20
- • Anti-Mullerian hormone (AMH) ≤3ng/ml (AMH result of up to one year will be valid)
- • Age \>=18 and ≤40 years
- • BMI \>18 and \<30 kg/m2
- Exclusion Criteria:
- • Medically indicated fertility preservation
- • AFC ≥ 20
- • Polycystic ovarian syndrome (PCOS) according to the Rotterdam criteria
- • FSH ≥ 20
- • History of untreated autoimmune, endocrine or metabolic disorders
- • Contraindication for hormonal treatment
- • Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).
About Fundación Santiago Dexeus Font
Fundación Santiago Dexeus Font is a leading clinical research organization dedicated to advancing medical science through innovative research and development initiatives. With a strong focus on enhancing patient care and outcomes, the foundation collaborates with healthcare professionals and institutions to conduct rigorous clinical trials across various therapeutic areas. Its commitment to ethical practices and adherence to regulatory standards ensures the integrity of research findings, while its emphasis on patient-centered approaches fosters a supportive environment for participants. Through these efforts, Fundación Santiago Dexeus Font aims to contribute significantly to the advancement of medical knowledge and the improvement of healthcare practices globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
Nikolaos P Polyzos, MD PhD
Study Chair
Hospital Universitari Dexeus
Ana Neves, MD
Principal Investigator
Hospital Universitari Dexeus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials